Bank of America
CNCR

Bank of America’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Bank of America’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$2K – 7873
2022
Q2 		$2K Buy
+100
New +$1.53K ﹤0.01% 7767

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Bank of America's CNCR Position: Q3 2022 in Review

Bank of America sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2022, closing a stake of 100 shares — an estimated $2K sold.

Bank of America first reported a position in CNCR in Q2 2022 and held it in 1 quarter. The position peaked at $2K in Q2 2022. 19 funds tracked by Wall St. Rank hold CNCR as of Q3 2022.

  • Bank of America reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2022 after selling out during the quarter.
  • Bank of America sold 100 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2022, an estimated $2K.
  • Bank of America first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2022 and held it in 1 quarter.
  • Bank of America's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $2K in Q2 2022.
  • 19 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2022.

Based on Bank of America's 13F filing for Q3 2022, filed 14 Nov 2022.